The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on KCa2.3/KCa3.1-EDH-type relaxation in rat small mesenteric arteries

Vascul Pharmacol. 2017 Dec:99:65-73. doi: 10.1016/j.vph.2017.10.001. Epub 2017 Oct 14.

Abstract

The aim of this study was to examine the influence of deoxycorticosterone acetate-salt (DOCA-salt) hypertension and chronic treatment with the fatty acid amide hydrolase inhibitor, URB597, on small and intermediate conductance calcium-activated potassium channels and endothelium-dependent hyperpolarization (KCa2.3/KCa3.1-EDH) in rat small mesenteric arteries (sMAs). The EDH-type response was investigated, in endothelium-intact sMAs using a wire myograph, by examining acetylcholine-evoked vasorelaxation in the presence of Nω-nitro-L-arginine methyl ester and indomethacin (inhibitors of nitric oxide synthase and cyclooxygenase, respectively). In normo- and hypertension the efficacy of EDH-type relaxation was similar and inhibition of KCa2.3 and KCa3.1 by UCL1684 and TRAM-34, respectively, given alone or in combination, attenuated EDH-mediated vasorelaxation. KCa3.1 expression and NS309 (KCa2.3/KCa3.1 activator)-induced relaxation was reduced in sMAs of DOCA-salt rats. Endothelium denudation and incubation with UCL1684 and TRAM-34 attenuated the maximal NS309-evoked vasorelaxation in both groups. URB597 had no effect in functional studies, but increased the expression of KCa3.1 in the sMAs. KCa2.3/KCa3.1-EDH-mediated relaxation was maintained in the sMAs of DOCA-salt rats despite endothelial dysfunction and down-regulation of KCa3.1. Furthermore, KCa3.1 played a key role in the EDH-type dilator response of sMAs in normo- and hypertension. The hypotensive effect of URB597 is independent of KCa2.3/KCa3.1-EDH-type relaxation.

Keywords: DOCA-salt hypertension; EDH-type relaxation; FAAH inhibitor; K(Ca)2.3; K(Ca)3.1.

MeSH terms

  • Amidohydrolases / antagonists & inhibitors*
  • Amidohydrolases / metabolism
  • Animals
  • Antihypertensive Agents / pharmacology*
  • Benzamides / pharmacology*
  • Carbamates / pharmacology*
  • Desoxycorticosterone Acetate
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Hypertension / drug therapy*
  • Hypertension / enzymology
  • Hypertension / etiology
  • Hypertension / physiopathology
  • In Vitro Techniques
  • Intermediate-Conductance Calcium-Activated Potassium Channels / metabolism*
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / enzymology
  • Mesenteric Arteries / physiopathology
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Small-Conductance Calcium-Activated Potassium Channels / metabolism*
  • Sodium Chloride, Dietary
  • Time Factors
  • Vasodilation / drug effects*
  • Vasodilator Agents / pharmacology*

Substances

  • Antihypertensive Agents
  • Benzamides
  • Carbamates
  • Enzyme Inhibitors
  • Intermediate-Conductance Calcium-Activated Potassium Channels
  • Kcnn3 protein, rat
  • Kcnn4 protein, rat
  • Small-Conductance Calcium-Activated Potassium Channels
  • Sodium Chloride, Dietary
  • Vasodilator Agents
  • cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
  • Desoxycorticosterone Acetate
  • Amidohydrolases
  • fatty-acid amide hydrolase